Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C Patients with Genotype 1b and High Virus Load

Yasuji Arase, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Satoshi Saito, Kenji Ikeda (+2 others)
2010 Internal medicine (Tokyo. 1992)  
Objective The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b. Methods Inclusion criteria were HCV-genotype 1b, serum HCV RNA level of !100 KIU/ml before the initiation of treatment. A total of 40 patients were enrolled in this retrospective cohort study. The treatment period of combination therapy was 48 weeks. Nonparametric procedures were employed for the
more » ... yed for the analysis of background features of the patients with SVR and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Of the 40 study patients, ten had mental disorders before the initiation of combination therapy. One of the patients stopped the treatment due to exacerbation of depression and another patient stopped due to a skin rash. Three patients suspended the therapy due to an insufficient response of positive serum HCV RNA at 24 weeks after the initiation of treatment. Thus, 34 patients completed combination therapy. Fifteen had sustained virological response (SVR). The SVR rate in patients who showed negative HCV RNA 8 weeks after the initiation of combination therapy was 86.7% (13/15). On the other hand, the SVR rate in patients who showed positive HCV RNA at 8 weeks was 8% (2/25) (p<.001). Continuous period of negative serum HCV RNA was 33.1 weeks in SVR groups, and 12.5 weeks in non-SVR groups (p<.001). (1-7) . Hence, combination therapy of peginterferon and ribavirin has been widely recommended as a first choice for chronic hepatitis C patients with high virus load. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for patients with type C hepatitis of genotype 1b and high virus load. Introduction Current evidence indicates that combination therapy of peginterferon and ribavirin (RBV) for hepatitis C virus (HCV) is associated with a higher rate of sustained virological response (SVR) compared with interferon (IFN) alone However, the dropout rates in patients treated with combination therapy of peginterferon and ribavirin was higher than those treated with IFN monotherapy (8, 9) . Previous studies indicated that 10-16% of patients treated with peginterferon and ribavirin for 48 weeks discontinued the therapy due to adverse effects (2, 10, 11) . Thus, there is an ongoing need to refine treatment strategies with strong effect and safety in HCV patients.
doi:10.2169/internalmedicine.49.3232 pmid:20519809 fatcat:yeqfn4bua5ej5ekh2zoisqriya